Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | AMG 510 for targeting KRAS G12C mutant solid tumours

Marwan Fakih • 29 Sep 2019
ESMO 2019
General Sotorasib

Marwan Fakih, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, gives an update on the study of AMG 510 (NCT03600883) that inhibits KRAS G12C in mutant solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Marwan Fakih

2:06
SPICE trial: enadenotucirev with nivolumab in tumors of epithelial origin
Marwan Fakih • 29 Sep 2019

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals